Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis

OBJECTIVES: To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA). METHODS: Children aged 2 to <18 years with active pc-JIA despite MTX therapy for ≥2 months received 80 mg/m(2) golimumab at weeks 0, 4, then every 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruperto, Nicolino, Brunner, Hermine I, Pacheco-Tena, César, Louw, Ingrid, Vega-Cornejo, Gabriel, Spindler, Alberto J, Kingsbury, Daniel J, Schmeling, Heinrike, Borzutzky, Arturo, Cuttica, Rubén, Inman, C J, Malievskiy, Victor, Scott, Christiaan, Keltsev, Vladimir, Terreri, Maria Teresa, Viola, Diego Oscar, Xavier, Ricardo M, Fernandes, Taciana A Pedrosa, Velázquez, María del Rocío Maldonado, Henrickson, Michael, Clark, Michael B, Bensley, Karen A, Li, Xiaoming, Lo, Kim Hung, Leu, Jocelyn H, Hsu, Chyi-Hung, Hsia, Elizabeth C, Xu, Zhenhua, Martini, Alberto, Lovell, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487314/
https://www.ncbi.nlm.nih.gov/pubmed/33493312
http://dx.doi.org/10.1093/rheumatology/keab021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487314/
https://www.ncbi.nlm.nih.gov/pubmed/33493312
http://dx.doi.org/10.1093/rheumatology/keab021

Ejemplares similares